ATE166656T1 - Humanes galanin, cdna-klone die für humanes galanin kodieren und eine methode humanes galamin herzustellen - Google Patents

Humanes galanin, cdna-klone die für humanes galanin kodieren und eine methode humanes galamin herzustellen

Info

Publication number
ATE166656T1
ATE166656T1 AT92906577T AT92906577T ATE166656T1 AT E166656 T1 ATE166656 T1 AT E166656T1 AT 92906577 T AT92906577 T AT 92906577T AT 92906577 T AT92906577 T AT 92906577T AT E166656 T1 ATE166656 T1 AT E166656T1
Authority
AT
Austria
Prior art keywords
human
galanin
galamine
code
cdna clones
Prior art date
Application number
AT92906577T
Other languages
English (en)
Inventor
Helen Frances Evans
John Shine
Original Assignee
Garvan Inst Med Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Garvan Inst Med Res filed Critical Garvan Inst Med Res
Application granted granted Critical
Publication of ATE166656T1 publication Critical patent/ATE166656T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
AT92906577T 1991-03-06 1992-03-06 Humanes galanin, cdna-klone die für humanes galanin kodieren und eine methode humanes galamin herzustellen ATE166656T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPK495391 1991-03-06

Publications (1)

Publication Number Publication Date
ATE166656T1 true ATE166656T1 (de) 1998-06-15

Family

ID=3775264

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92906577T ATE166656T1 (de) 1991-03-06 1992-03-06 Humanes galanin, cdna-klone die für humanes galanin kodieren und eine methode humanes galamin herzustellen

Country Status (6)

Country Link
EP (1) EP0587571B1 (de)
JP (1) JP3135262B2 (de)
AT (1) ATE166656T1 (de)
CA (1) CA2105572A1 (de)
DE (1) DE69225706T2 (de)
WO (1) WO1992015681A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU730137B2 (en) 1996-01-24 2001-03-01 H. Lundbeck A/S DNA encoding galanin GALR2 receptors and uses thereof
US5972624A (en) * 1996-01-24 1999-10-26 Synaptic Pharmaceutical Corporation Method of identifying ligands which bind recombinant galanin receptor (GALR2)
AU3630297A (en) * 1996-07-24 1998-02-10 University Of Bristol, The Galanin
US6329197B2 (en) 1996-10-09 2001-12-11 Synaptic Pharmaceutical Corporation DNA encoding galanin GALR3 receptors and uses thereof
WO1999031130A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Galanin receptor galr3 and nucleotides encoding same
US7217762B1 (en) 1999-04-09 2007-05-15 Invitrogen Corporation Process for the preparation of monodisperse polymer particles
US7927597B2 (en) 2001-04-10 2011-04-19 Agensys, Inc. Methods to inhibit cell growth
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
JP2008517930A (ja) 2004-10-21 2008-05-29 トランス テック ファーマ，インコーポレイテッド ＧａｌＲ１のアゴニストとしてのビススルホンアミド化合物、組成物、及び使用法
GB0523550D0 (en) 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds
WO2009039982A2 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012997A1 (en) * 1991-01-16 1992-08-06 The General Hospital Corporation Human galanin
AU1462692A (en) * 1991-02-25 1992-09-15 Board Of Regents Of The University Of Washington, The Methods for detecting galanin antagonists

Also Published As

Publication number Publication date
DE69225706D1 (de) 1998-07-02
EP0587571A1 (de) 1994-03-23
JP3135262B2 (ja) 2001-02-13
EP0587571A4 (de) 1995-03-15
CA2105572A1 (en) 1992-09-07
DE69225706T2 (de) 1998-11-26
EP0587571B1 (de) 1998-05-27
JPH06508984A (ja) 1994-10-13
WO1992015681A1 (en) 1992-09-17

Similar Documents

Publication Publication Date Title
ATE229072T1 (de) Für den vorläufer des für die tumorabstossung verantwortlichen antigens mage-3 kodierendes, isoliertes nukleinsäuremolekül und seine verwendung
ATE182901T1 (de) Für androgen-rezeptor-protein kodierende dna
TW327194B (en) Novel amyloid precursor proteins and methods of using same
HUT46356A (en) Process for producing the preprotein of apc polypeptide and the dna encoding it, as well as for the diagnostic utilization of the dna and the protein
ATE166656T1 (de) Humanes galanin, cdna-klone die für humanes galanin kodieren und eine methode humanes galamin herzustellen
DE69617440D1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
DE69433790T2 (de) Isolierte peptide, die mit mhc mulekül hla-c-klon 10 komplexe bilden und ihre verwendungen
BR9710665A (pt) Compostos que promovem o desenvolvimento do tecido
BR0209528A (pt) Proteìnas de ligaçaõ de peptìdeo beta-amilóide e polinucleotìdeos codificando as mesmas
DK413488D0 (da) Dna-klon med en basissekvens for human vaevsfaktorinhibitor (tfi) og dna-sekvens, der koder for tfi
FI900808A0 (fi) Humant mannos bindande protein.
LU93259I2 (fr) LETIFEND (Protein Q)
NZ332369A (en) Isolated nucleic acid molecules which code for GAGE tumor rejection antigen, the tumor rejection antigen, and uses thereof
UA39165C2 (uk) Молекула днк, що кодує ліпазу людини, що стимулюється солями жовчних кислот, клонована молекула кднк
NO930428L (no) Proteinstrukturen til plantetoksingelonin
ATE108830T1 (de) Dns-sequenzen, rekombinante dns-moleküle und verfahren zur herstellung menschlicher lipocortinähnlicher polypeptide.
ATE490979T1 (de) Neueskollagen-ähnliches protein clac, dessen vorläufer und dafür kodierende gene
ATE395602T1 (de) Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
DE69534470T2 (de) Lgmd- gen kodierend für eine calcium-abhängige protease
ATE331032T1 (de) Glutamine: fructose-6-phosphat amidotransferase (gfat), ihre herstellung und verwendung
HUP9900789A2 (hu) Lefelé irányuló szabályozásra rezisztens C3 konvertáz
PT704527E (pt) Sequencias de adn que codificam precursores de insulina biossinteticos e processo para a preparacao de insulina
DE59410423D1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
DK595187A (da) Minactivin og fremgangsmaade til fremstilling deraf
EP0826041A4 (de) Transformierender wachstumsfaktor alpha hii (tg1f & hii)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties